A Multicentre Phase II Study of Docetaxel plus Cisplatin for the Treatment of Advanced Gastric Cancer

Fahlke, J.; Ridwelski, K.; Schmidt, C.; Hribaschek, K.; Stuebs, Patrick; Kettner, E.; Quietzsch, D.; Aßmann, Michael; Deist, Tillman; Keilholz, Ulrich; Lippert, H.

doi:10.1159/000110042

Cited by 8 publications

(3 citation statements)

References 37 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Allerdings wurden keine Phase-III-Studien zum Nachweis der Nicht-Unterlegenheit dieser Schemata im Vergleich zum klassischen DCF durchgeführt. Docetaxel-haltige Zweifachkombinationen (DF oder CF) zeigten in randomisierten Studien im Vergleich zu CF keine Verbesserung der Wirksamkeit[436,437] und stellen keine Alternative zum DCF dar (• ▶ Tab. 2).Studie, in welche 60 Patienten/Arm eingeschlossen werden sollten, ist nach Einschluss von insgesamt 40 Patienten über 4 Jahre wegen mangelnder Rekrutierung abgebrochen worden und liegt bisher nur als Abstract vor[444].…”

unclassified

S3-Leitlinie „Magenkarzinom” -

Moehler¹,

Al-Batran²,

Andus³

et al. 2011

Z Gastroenterol

Self Cite

254

View full text Add to dashboard Cite

unclassified

S3-Leitlinie „Magenkarzinom” -

Moehler¹,

Al-Batran²,

Andus³

et al. 2011

Z Gastroenterol

Self Cite

254

View full text Add to dashboard Cite

“…The activity of docetaxel in gastric cancer was first demonstrated in phase II single-agent studies: reported overall response rates (ORRs) were 16-24 % in the first-line setting [13][14][15][16][17]. The combination of docetaxel and cisplatin (DC) as a first-line chemotherapy was revealed to have a modest anti-tumor effect and manageable toxicity for the palliative treatment of AGC [18][19][20].…”

Section: Introductionmentioning

confidence: 99%

Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma

et al. 2012

View full text Add to dashboard Cite

Background The combination of docetaxel, cisplatin, and 5-fluorouracil (DCF) is an effective but highly toxic regimen for the treatment of advanced gastric cancer. To improve tolerability while maintaining the efficacy of the DCF regimen, we developed a modified DCF regimen including an infusional 5-fluorouracil administration according to the de Gramont regimen. Methods In this study, 70 patients with advanced gastric cancer were treated. Each 2-week cycle consisted of docetaxel (60 mg/m 2 ), cisplatin (50 mg/m 2 ), a 5-fluorouracil (400 mg/m 2 ) IV bolus, and 5-fluorouracil (2,400 mg/m 2 ) IV over 46 h plus leucovorin (400 mg/m 2 ) IV over 2 h. Results The median progression-free survival and overall survival were 9.0 months (95 % CI, 7.1-10.9) and 10.8 months (95 % CI, 7.4-14.2), respectively; the 1-year and 2-year overall survival rates were 46.3 and 18.4 %, respectively. Twenty-nine (41.4 %) partial responses, 19 (27.1 %) stable disease, and 22 (31.4 %) progression of disease were observed. Grade 3-4 toxicities included neutropenia (37.1 %), febrile neutropenia (15.7 %), thrombocytopenia (10.0 %), anemia (8.6 %), nausea and vomiting (10.0 %), stomatitis (5.7 %), infection (8.6 %), and diarrhea (2.9 %). ConclusionsOur results show that a de Gramont-based DCF regimen may have tolerable toxicities and be an effective and convenient palliative treatment for advanced gastric cancer.

show abstract

“…In the recent 10 years, taxanes have been introduced in treatment of advanced gastric cancer [12]. It was reported that docetaxel monotherapy has a response rate of up to 24% [13].…”

Section: Introductionmentioning

confidence: 99%

Comparison of Cisplatin-5-Fluorouracil-Folinic Acid versus Modified Docetaxel-Cisplatin-5-Fluorouracil Regimens in the First-Line Treatment of Metastatic Gastric Cancer

Köş¹,

Uncu²,

Özdemir³

et al. 2011

Chemotherapy

View full text Add to dashboard Cite

Objective: Prognosis of metastatic gastric cancer is poor and median survival is between 3 and 5 months. Response rates of combination chemotherapy with 5-fluorouracil (5-FU) and cisplatin in first-line treatment have been found to be 20–25% in the English literature. It has been demonstrated that adding docetaxel to combination chemotherapy improved time to progression and overall survival. However, the toxicity rates of the docetaxel-cisplatin-5-FU protocol were high. In our study we compared efficacy and toxicity of cisplatin-5-FU-folinic acid (CFF) and modified docetaxel-cisplatin-5-FU (mDCF) regimens in the first-line treatment of metastatic gastric cancer. Patients and Methods: Between June 2004 and October 2008, 70 patients with previously untreated metastatic gastric cancer treated with CFF (n = 30) and mDCF (n = 40) were retrospectively evaluated in the study. Survival and toxicity data were compared. Results: Median age of the patients was 53 years (range 23–69). Forty-eight percent of the patients were male and 75.7% had an ECOG performance status of 0–1. Prognostic factors including age, ECOG performance status, histopathological grade, and number and sites of metastases were similar between the groups. Objective response rates (complete and partial response) were higher in the mDCF group (30.0 vs. 13.3%, p = 0.19). While toxicity was acceptable in both groups, the most common grade 3–4 toxicities were anemia in 3.3 and 5.0%, neutropenia in 20 and 7.5%, febrile neutropenia in 6.7 and 5.0%, and diarrhea in 3.3 and 5.0% in the CFF and mDCF groups, respectively. Median follow-up was 10.3 (1.5–59.6) months. During that period 90 and 97.5% of the patients were dead in the CFF and mDCF groups, respectively. Median time to progression was 4.4 (95% CI 1.8–7.0) and 6.2 months (95% CI 5.6–6.8) (p = 0.85), median overall survival was 6.5 (95% CI 1.8–11.2) and 8.7 months (95% CI 6.7–10.7) (p = 0.88) in the CFF and mDCF groups, respectively. Conclusion: The mDCF regimen has been found to be more favorable than the CFF regimen with an acceptable toxicity profile in the first-line treatment of metastatic gastric cancer.

show abstract

A Multicentre Phase II Study of Docetaxel plus Cisplatin for the Treatment of Advanced Gastric Cancer

Cited by 8 publications

References 37 publications

S3-Leitlinie „Magenkarzinom” -

S3-Leitlinie „Magenkarzinom” -

Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma

Comparison of Cisplatin-5-Fluorouracil-Folinic Acid versus Modified Docetaxel-Cisplatin-5-Fluorouracil Regimens in the First-Line Treatment of Metastatic Gastric Cancer

Contact Info

Product

Resources

About